entertainment -WSS

entertainment

author：hotspot 2025-09-30 18:20:34 - browse：4

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Steward Health Care expansion into Malta flopped

leisure time

WSS

Bring on the sabbaticals for nurses

3 trends to watch in health tech's hiring outlook for 2024

3 medical device trends to watch in 2024

Feng Zhang, Grail founder join forces on new gene editing startup

Texas board proposes rules on abortion law emergency exemption

Yancopoulos of Regeneron works to expand Dupixent success

focus

entertainment

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

GSK Flovent asthma inhalers replaced by authorized generics

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Antibiotic resistance and the global rise in human conflict

Medicare details structure of new drug price negotiation program

The FDA must approve intranasal treatments for anaphylaxis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

BioMarin wins approval for gene therapy to treat hemophilia A

Morgan Health, with ambitious aims, wants you to know it’s still here

hotspot

AdventHealth escalates lawsuit against insurance vendor Multiplan

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Videos point to link between seizures and unexplained toddler deaths

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Federal weight loss drug coverage is 30 years out of date

Steward Health Care expansion into Malta flopped

explore

explore

leisure time

Wikipedia